Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS
tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or
carboplatin and thiotepa conditioning (for CNS tumors) followed by an autologous peripheral
blood stem cell transplant. For solid tumors, if appropriate, disease specific radiation
therapy at day +60. For CNS tumors, the conditioning regimen and autologous peripheral blood
stem cell transplant will be given for 3 cycles.